查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
多关节型青少年特发性关节炎药物全球市场-2022-2029
市场调查报告书
商品编码
1140671

多关节型青少年特发性关节炎药物全球市场-2022-2029

Global Polyarticular Juvenile Idiopathic Arthritis Drugs Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

到 2021 年，多关节型幼年特发性关节炎治疗市场规模估计为 15.884 亿美元，在 2022-2029 年的预测期内达到 6.60% 的复合年增长率 (CAGR)。

幼年特发性关节炎 (JIA) 是儿童和青少年最常见的关节炎类型之一。幼年特发性关节炎是一种慢性炎症性疾病，分为六类：全身性、少突型、多关节型、跟腱炎相关、银屑病型和未分化型。JIA 在 16 岁之前开始并持续至少 6 週。美国约有 300,000 名儿童患有 JIA。

多关节型幼年特发性关节炎 (PJIA) 影响五个或更多关节，包括手脚的小关节和膝、髋、踝等大关节。PJIA 会影响手指和手部的小关节，但也会影响负重关节和下巴。症状包括发烧、粉红色皮疹、眼睛刺激、关节疼痛、关节肿胀以及骨骼发育和生长问题。治疗包括止痛药、非甾体抗炎药和改善疾病的抗风湿药。

市场动态

多关节幼年特发性关节炎发病率的增加正在推动市场增长。

据估计，美国约有 300,000 名儿童患有某种形式的关节炎。JIA发病率估计为每年每10万人4-14例，JRA患病率估计为每10万人1.6-86.1例。儿童关节炎的发病率从日本的每 100,000 人 0.83 到挪威的每 100,000 人 23 不等。世界范围内的发病率正在增加。Pruunsild 等人报告说，爱沙尼亚连续第三年增长了 3.5 倍。患病率从台湾的 3.8/100,000 到澳大利亚的一项社区研究中的 400/100,000 不等。

因此，随着幼年特发性关节炎（JIA）发病率的增加，私人製造商和研究机构正在积极进行治疗药物的研发。几项临床试验正在进行中，以扩大 PJIA 治疗的潜力。

流行病学

幼年特发性关节炎是儿童期最常见的慢性风湿性疾病之一。在高收入国家，年发病率估计为每 100,000 人 2-20 例。这些地区的患病率估计为每 100,000 人 16-150 例。一项针对西澳大利亚学童的区域研究报告称，每 100,000 人中有 400 人患病。总体而言，患病率通常被概括为千分之一的儿童。

不同人群和种族的发病率和流行率数据不同，非洲裔加勒比和亚洲人群的流行率较低。JIA亚型的频率也存在种族差异。例如，多发性关节炎是欧洲人的常见亚型，但多发性关节炎在印度、哥斯达黎加、新西兰和南非等许多其他国家占主导地位。

市场细分

全球多关节幼年特发性关节炎治疗市场根据药物类型和分销渠道进行细分。

按药物类型来看，治疗多关节幼年特发性关节炎的双羟□酸有望迅速增长。

按药物类型，多关节型幼年特发性关节炎药物市场分为改善疾病的抗风湿药（DMARDs）、生物製剂、非甾体抗炎药和糖皮质激素。

非甾体抗炎药：NSAIDs通过抑制环加氧□ (COX) 来干扰前列腺素的合成，从而减轻肿胀和疼痛。NSAIDs用于治疗 JIA 的所有亚型。它可以有效缓解疼痛和减少肿胀。常用的非甾体抗炎药包括□普生、布洛芬、托美汀、双氯芬酸和消炎痛。

美洛昔康（Movic）：美洛昔康属于非甾体抗炎药的烯醇家族，在结构上与□罗昔康相关。Movic 用于缓解 2 岁及以上儿童小关节或多关节关节的幼年类风湿性关节炎症状。

□普生（Aleve、Naprelan、Naprosyn）：□普生是一种镇痛剂和抗炎药，用于治疗关节疼痛和关节炎。□普生适用于治疗类风湿性关节炎、骨关节炎、强直性脊柱炎、多关节幼年特发性关节炎、肌腱炎、滑囊炎、急性痛风、原发性痛经和轻度至中度疼痛。有缓解作用。

改善疾病的抗风湿药 (DMARDs)：DMARDs 可以减缓或预防疾病进展，从而防止关节破坏和相关的功能衰退。DMARDs 的成功治疗可以消除对其他抗炎和止痛药的需求。然而，在 DMARD 完全有效之前，可能需要抗炎和镇痛药物作为减轻疼痛和肿胀的桥樑。

Sulfasalazine (Azulfidine, EN-tab)：在治疗对水杨酸盐和其他非甾体类抗炎药反应不充分的多关节型幼年类风湿性关节炎的儿科患者中，降低炎症反应并降低炎症反应。全身抑制前列腺素合成.

生物製剂：结合 TNF 并阻断其与其受体相互作用的 TNF 抑製剂，如依那西普、英夫利昔单抗和阿达木单抗。

依那西普：2019年4月，FDA批准了依那西普的第二种生物仿製药依那西普-依那西普，用于所有符合条件的生物适应症。Eticovo (etanercept-ykro, Samsung Bioepis) 是 Enbrel (etanercept, Amgen) 的生物仿製药，推荐用于患有强直性脊柱炎、斑块型银屑病、多关节型幼年特发性关节炎、银屑病关节炎和类风湿性关节炎的患者。它是一种 TNF 抑製剂，用于治疗目的.获得该批准后，Eticovo 成为第二个获准在美国使用的 Enbrel 生物仿製药。

Tocilizumab LusiNEX (Tocilizumab, Mysenac) 是一种具有白细胞介素 6 受体 (IL-6R) 拮抗剂活性的生物类似药。通过与 IL-6R 结合，它可以抑制炎症反应并减轻关节侵蚀。Actemra/Roa Actemra 适用于类风湿性关节炎 (RA)、巨大淋巴结增生 (Castleman 病)、多关节特发性关节炎 (PJIA) 和全身性幼年特发性关节炎 (SJIA)。

阿达木单抗：2022年8月17日，Samsung Bioepis Co., Ltd.和Organon Co., Ltd.收到来自美国的Humira（阿达木单抗）生物类似药HADLIMA（阿达木单抗-bwwd）的无柠檬酸盐高浓度製剂。食品和药物管理局 (FDA). 100mg/ml) 获得批准。

地理渗透

北美在多关节幼年特发性关节炎药物的全球市场中占有最大的市场份额。

由于幼年特发性关节炎患病率的上升和多关节型幼年特发性关节炎药物的开发不断增加，北美地区在全球多关节型幼年特发性关节炎药物市场中占据主导地位，在 2021 年占据最大的市场份额。例如，2020 年 4 月，Johnson & Johnson旗下Janssen Pharmaceutical Companies宣布，幼年特发性多关节关节炎（DJIA）和幼年银屑病关节炎（DJIA）联合甲氨蝶呤治疗 2 岁及以上患者（jPsA）我们已经提交了两份生物製品许可证向美国食品和药物管理局 (FDA) 提交的补充申请 (sBLA)，寻求批准 SIMPONI ARIA (golimumab) 用于治疗用途。

同样在 2021 年 2 月 24 日，美国上市生物製药公司AbbVie获得美国食品和药物管理局批准 HUMIRA 用于治疗 5 岁及以上儿童患者的中度至重度活动性溃疡性结肠炎（阿达木单抗）。已被批准。

竞争格局

多关节型幼年特发性关节炎药物市场竞争激烈。由于新药开发的增加，少数中小企业可能会在预测期内进入市场。为市场增长做出贡献的主要公司包括Pfizer Inc.、Biocon Ltd.、Coherus BioSciences Inc.、Livzon Pharmaceutical Group Inc.、Myenta Pharmaceuticals Inc.。Momenta Pharmaceuticals Inc.、Mycenax Biotech Inc.、Oncobiologics Inc.、Oncodesign SA、Panacea Biotec Ltd.、Regeneron Pharmaceuticals Inc.、Sandoz International GmbH、UCB SA 等。主要参与者正在采取多种增长战略，包括产品发布、收购和合作伙伴关係，这些战略正在促进全球多关节幼年特发性关节炎治疗市场的增长。

Pfizer Inc.

概述

Pfizer Inc.是一家总部位于纽约的美国製药公司。该公司为广泛的医学领域开发和生产药物和疫苗，包括免疫学、肿瘤学、心脏病学、内分泌学和神经学。产品包括降低 LDL 胆固醇的重磅炸弹立普妥（阿托伐他汀）、神经性疼痛和纤维肌痛药物 Lyrica（普瑞巴林）、口服抗真菌药物 Diflucan（氟康唑）、抗生素 Zithromax（阿奇霉素）、治疗勃起功能障碍的伟哥（西地那非）、和抗炎药Celebrex（也称为Cerebra，celecoxib）。

产品介绍

XELJANZ（託法替尼）。在美国，甲氨蝶呤难治的中度至重度活动性类风湿关节炎 (RA)、改善疾病的抗风湿药物 (DMARD) 和肿瘤坏死因子抑製剂 (TNFi) 难治的活动性银屑病关节炎 (PSA) 已批准用于中度- 至重度活动性溃疡性结肠炎 (UC)、活动性多关节病程幼年特发性关节炎 (pcJIA)（□2 岁患者）。

重大发展

2020年9月28日，Pfizer Inc.宣布XELJANZ（託法替尼）获美国食品药品监督管理局（FDA）批准，用于治疗2岁及以上活动性多关节幼年特发性关节炎（pcJIA）儿童和青少年获得批准。这次批准的是两种剂型，一种是片剂，一种是内服，剂量是根据体重来的。该批准使 XELJANZ 成为美国第一个也是唯一一个批准用于治疗 pcJIA 的 Janus 激□（ JAK ）抑製剂。

COVID-19 对数字 X 射线全球市场的负面影响

COVID-19 正在通过直接影响生产和需求、扰乱供应炼和扰乱市场以及对企业和金融市场产生财务影响来影响全球经济。全球多关节型幼年特发性关节炎治疗市场受到 COVID-19 流行病的影响，由于人数不断增加，利益相关者呼吁采用新的方法来诊断和治愈受 COVID-19 影响的患者。

2020 年 5 月，台湾合同研究和製造组织 (CDMO) Mycenax 同意向匈牙利的 Gedeon Richter 出售一种托珠单抗 (LusiNEX) 的生物仿製药。

一种有可能治疗与冠状病毒病（COVID-19）相关的肺炎的研究性生物仿製药产品将以 1650 万美元的价格出售。该生物类似药是基于Roche Actemra开发的托珠单抗製剂。儘管该产品旨在用于类风湿性关节炎的二线治疗，但最近的证据表明它可能在对抗 COVID-19 方面具有治疗价值。

LusiNEX 目前处于 1 期试验阶段，自 2013 年以来一直在开发中。Gedeon Richter 预计将于 2025 年在欧盟、加拿大、澳大利亚和日本上市销售。目前美国市场上没有托珠单抗生物类似药。罗氏 Actemra 的全球销售额估计为 24 亿美元。

FDA 还在进行一项 3 期研究，以评估静脉注射托珠单抗（“Actemra”）与 COVID-19并发症住院成人的护理标准的安全性和有效性。已批准临床试验。该研究将评估该药物是否可以减少不受控制的炎症，这种炎症会损害患者的肺部并增加通气和死亡的风险。在某些 COVID-19 病例中，免疫系统可能变得过度活跃并产生危及生命的细胞因子风暴。武汉的中国医生去年报告了使用托珠单抗治疗少数严重肺损伤的 COVID-19 患者的可喜结果。托珠单抗现已纳入中国 COVID-19 治疗指南。

目录

第一章 调查方法和范围

  • 调查方法
  • 市场范围

第二章主要趋势和发展

第三章执行摘要

  • 按药物类型划分的市场细分
  • 按分销渠道划分的市场细分
  • 区域市场细分

第四章市场动态

  • 市场影响因素
    • 促进者
      • 骨科领域病例增加推动市场增长
      • 数字 X 射线设备的技术进步
    • 约束
      • 辐射暴露的副作用风险
    • 商机
  • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 医疗费用分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 中的价格动态
  • 供需谱
  • 大流行期间与市场相关的政府努力
  • 製造商的战略举措
  • 概括

第 7 章 按药物类型

  • 改善疾病的抗风湿药
    • 柳氮磺胺□啶
    • 来氟米特
    • 甲氨蝶呤
    • 其他
  • 非甾体抗炎药
    • 美洛昔康
    • □普生
      • 阿雷夫
      • 那不勒兰
      • □普生
    • 其他
  • 生物製品
    • 阿巴西普
    • 阿达木单抗
    • 依那西普
    • 英夫利昔单抗
    • 利妥昔单抗
    • 托珠单抗
    • 其他
  • 皮质类固醇
  • 其他

第8章按销售渠道

  • 医院药房
  • 零售药店
  • 网上药店
  • 其他

第9章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美地区
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东/非洲

第 10 章 竞争格局

  • 竞争情景
  • 竞争对手战略分析
  • 市场/份额分析
  • 併购分析

第十一章公司简介

  • Pfizer Inc.
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Biocon Ltd.
  • Coherus BioSciences Inc.
  • Livzon Pharmaceutical Group Inc.
  • Momenta Pharmaceuticals Inc.
  • Mycenax Biotech Inc.
  • Oncobiologics Inc.
  • Oncodesign SA
  • Panacea Biotec Ltd.
  • Regeneron Pharmaceuticals Inc.
  • Sandoz International GmbH
  • UCB SA List not Exhaustive

第 12 章 数据管理

简介目录
Product Code: DMPH2748

Market Overview

Polyarticular Juvenile Idiopathic Arthritis Drugs Market size was valued at USD 1,588.40 million in 2021 and is estimated to reach at a compound annual growth rate (CAGR) of 6.60% over the forecast period 2022 to 2029.

Juvenile idiopathic arthritis (JIA) is one of the most common types of arthritis in kids and teens. Juvenile idiopathic arthritis is a chronic inflammatory disease that includes six categories: systemic, oligoarticular, polyarticular, enthesitis-related, psoriatic, and undifferentiated. JIA begins before 16 years of age and persists for at least six weeks. Around 300,000 children in the U.S. have a form of JIA.

Polyarticular juvenile idiopathic arthritis (PJIA) affects five or more joints and affects both the small joints of the hands and feet, and large joints like the knees, hips, and ankles. PJIA causes inflammation in small joints of the fingers and hands, but weight-bearing joints and the jaw can also be affected. Symptoms include fevers, pink rash, eye inflammation, joint pain, joint swelling, and problems with bone development and growth. Some of the treatment includes painkillers, NSAIDs, and disease-modifying anti-rheumatic drugs.

Market Dynamics

The increasing incidence of Polyarticular juvenile idiopathic arthritis is driving the market growth

Approximately 300,000 children in the United States are estimated to have some type of arthritis. The incidence rate estimates for JIA range from 4-14 cases per 100,000 children annually; for JRA, the prevalence has ranged from 1.6 to 86.1 cases per 100,000. The incidence of childhood arthritis ranges from 0.83 per 100,000 children in Japan to 23 per 100,000 in Norway. The incidence rate is increasing globally. Pruunsild et al. reported a 3.5-fold increase over three consecutive years in Estonia. The prevalence rate varies considerably more, spanning from 3.8 per 100,000 children in Taiwan to 400 per 100,000 in one community-based study in Australia.

Hence, the increasing incidence of juvenile idiopathic arthritis (JIA)is leading to a rise in research and development for its treatment by private manufacturers and research organizations. Several clinical trials are undergoing to expand the potential future of PJIA drugs.

Epidemiology

Juvenile Idiopathic Arthritis is one of the most common, chronic rheumatic diseases of childhood. In high-income countries, the annual incidence is estimated to be 2-20 cases per 100,000 population. The prevalence in these areas is estimated to be 16-150 cases per 100,000 population. According to one community-based survey of school children in Western Australia, it was reported that the prevalence is 400 per 100,000. Overall, the prevalence is often summarized as one per thousand children.

Incidence and prevalence data vary across the different populations and ethnic groups, with a lower prevalence in the Afro-Caribbean and Asian populations. There are also some ethnic differences in the frequency of JIA subtypes: for instance, oligoarthritis is a common subtype in European populations, whilst polyarticular disease predominates in many other countries including India, Costa Rica, New Zealand, and South Africa.

Market Segmentation

The global polyarticular juvenile idiopathic arthritis drugs market is segmented based on Drug Type and Distribution Channel.

By Drugs type, Polyarticular Juvenile Idiopathic Arthritis Drugs Pamoate is expected to witness rapid growth

Based on drug type, the polyarticular juvenile idiopathic arthritis drugs market is segmented into disease-modifying antirheumatic drugs (DMARDs), biologics, NSAIDs, and Glucocorticoids.

Nonsteroidal Anti-inflammatory Drugs: NSAIDs interfere with prostaglandin synthesis through inhibition of the enzyme cyclooxygenase (COX), thus reducing swelling and pain. NSAIDs are used to treat all subtypes of JIA. They may help with pain and decrease swelling. Commonly used NSAIDs include naproxen, ibuprofen, tolmetin, diclofenac, and indomethacin.

Meloxicam (Mobic): Meloxicam is a member of the enolic class of NSAIDs and is structurally related to piroxicam. MOBIC is indicated for relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age and older.

Naproxen (Aleve, Naprelan, Naprosyn): Naproxen is used for analgesic and anti-inflammatory properties, treating arthralgia and arthritis. Naproxen is indicated for the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain.

Disease-Modifying Antirheumatic Drugs: DMARDs can retard or prevent disease progression and, thus, joint destruction and subsequent loss of function. Successful DMARD therapy may eliminate the need for other anti-inflammatory or analgesic medications; however, until the full action of DMARDs takes effect, anti-inflammatory or analgesic medications may be required as bridging therapy to reduce pain and swelling.

Sulfasalazine (Azulfidine, EN-tabs): Sulfasalazine decreases the inflammatory response and systemically inhibits prostaglandin synthesis. in the treatment of pediatric patients with polyarticular-course juvenile rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs.

Biologics: The TNF blockers, which bind TNF and thus prevent its interaction with its receptors, include etanercept, infliximab, and adalimumab, among others

Etanercept: In April 2019, the FDA has approved the second biosimilar to etanercept, etanercept-ykro, for all eligible indications of the biological product. Eticovo (etanercept-ykro, Samsung Bioepis), a biosimilar to Enbrel (etanercept, Amgen), is a TNF-inhibitor intended to treat patients with ankylosing spondylitis, plaque psoriasis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, and rheumatoid arthritis. With this approval, Eticovo becomes the second biosimilar to Enbrel approved for use in the United States.

Tocilizumab: LusiNEX (Tocilizumab, Mycenax in-house), a biosimilar act as interleukin-6 receptor (IL-6R) antagonist. By binding IL-6R, it blocks the inflammatory response and alleviates joint erosion. The indication of Actemra/ RoActemra includes Rheumatoid arthritis (RA), giant lymph node hyperplasia (Castleman's disease), polyarticular idiopathic juvenile arthritis (PJIA), and systemic juvenile idiopathic arthritis (SJIA).

Adalimumab: On 17th August 2022, Samsung Bioepis Co., Ltd. and Organon & Co. announced that The United States Food and Drug Administration had approved the citrate-free, high concentration (100 mg/mL) formula of HADLIMA (adalimumab-bwwd), is a biosimilar referencing HUMIRA (adalimumab).

Geographical Penetration

North America region holds the largest market share in the global polyarticular juvenile idiopathic arthritis drugs market

North American region is dominating the global polyarticular juvenile idiopathic arthritis drugs market and accounted for the largest market share in 2021, owing to the rising prevalence of juvenile idiopathic arthritis and increasing development of drugs for the treatment of polyarticular juvenile idiopathic arthritis. For instance, in April 2020, the Janssen Pharmaceutical Companies of Johnson & Johnson submitted two supplemental Biologics License Applications (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis (DJIA) and juvenile psoriatic arthritis (jPsA), in patients two years of age and older in combination with methotrexate.

Also, on 24th February 2021, AbbVie, an American- based publicly traded biopharmaceutical company, announced that The United States Food and Drug Administration had approved HUMIRA (adalimumab) for treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older.

Competitive Landscape:

The polyarticular juvenile idiopathic arthritis drugs market is competitive. The rising drug development may witness the entry of a few small- or mid-sized companies into the market during the forecast period. Some of the key players which are contributing to the growth of the market include Pfizer Inc., Biocon Ltd., Coherus BioSciences Inc., Livzon Pharmaceutical Group Inc. Momenta Pharmaceuticals Inc., Mycenax Biotech Inc., Oncobiologics Inc., Oncodesign SA, Panacea Biotec Ltd., Regeneron Pharmaceuticals Inc., Sandoz International GmbH, UCB SA, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Polyarticular Juvenile Idiopathic Arthritis Drugs market globally.

Pfizer Inc.

Overview:

Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. Its products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin) for neuropathic pain and fibromyalgia; Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil) for erectile dysfunction; and Celebrex (also Celebra, celecoxib), an anti-inflammatory drug.

Product Portfolio:

XELJANZ (tofacitinib): It is approved in the U.S. in four indications: adults with moderately to severely active rheumatoid arthritis (RA) after methotrexate failure, adults with active psoriatic arthritis (PsA) after disease-modifying antirheumatic drug (DMARD) failure, adults with moderately to severely active ulcerative colitis (UC) after tumor necrosis factor inhibitor (TNFi) failure, and patients 2 years of age or older with active polyarticular course juvenile idiopathic arthritis (pcJIA).

Key Development:

On 28th September 2020, Pfizer received the United States (US) Food and Drug Administration (FDA) approval for XELJANZ (tofacitinib) for the treatment of children and adolescents two years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight. This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the US for the treatment of pcJIA.

COVID-19 Impact: Negative impact on the global Digital X-ray Market

COVID-19 is affecting the global economy by directly affecting production and demand, disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets. The global polyarticular juvenile idiopathic arthritis drugs market has been impacted by the COVID-19 pandemic, as stakeholders are increasingly searching for newer approaches to diagnosing and curing patients affected by the COVID-19.

In May 2020, Taiwan-based Mycenax, a pharmaceutical contract development and manufacturing organization (CDMO), agreed to sell its tocilizumab biosimilar (LusiNEX) to Hungary-based Gedeon Richter.

A biosimilar under development has the potential for treating coronavirus disease (COVID-19) related pneumonia is changing hands in a US$ 16.5 million deal. The biosimilar is a tocilizumab version that references Roche's Actemra. It is intended for the second-line treatment of rheumatoid arthritis, but recent evidence suggested that it has value as an agent in the war on COVID-19.

LusiNEX is currently being tested in a phase 1 trial and has been in development since 2013. Gedeon Richter is estimated to launch in the European Union, Canada, Australia, and Japan by 2025. Currently, there are no tocilizumab biosimilars on the U.S. market. Roche's Actemra has global sales estimated at $2.4 billion.

In addition, the FDA has approved a phase 3 clinical trial to evaluate the safety and efficacy of intravenous tocilizumab (Actemra) plus standard of care in hospitalized adult patients with pneumonia as a complication of COVID-19. The trial would assess if the agent can reduce uncontrollable inflammation that causes damage to patients' lungs and heightens risks for ventilation and death. In several cases of COVID-19, the immune system becomes overactive and generates a cytokine storm that can be life-threatening. Chinese physicians in Wuhan last year used tocilizumab to treat a small number of patients with COVID-19 with serious lung damage and reported promising results. Tocilizumab is now incorporated into Chinese guidelines for the treatment of COVID-19.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Drug Type
  • 3.2. Market Snippet by Distribution Channel
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
      • 4.1.1.1. The prevalence of orthopedic cases will drive the market growth.
      • 4.1.1.2. Technological advancements in digital X-ray devices
    • 4.1.2. Restraints
      • 4.1.2.1. Risk of adverse effects from radiation exposure
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Drug Type Segment
    • 7.1.2. Market attractiveness index, By Drug Type Segment
  • 7.2. Disease-modifying antirheumatic drug*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Sulfasalazine
    • 7.2.4. Leflunomide
    • 7.2.5. Methotrexate
    • 7.2.6. Others
  • 7.3. Nonsteroidal anti-inflammatory drugs
    • 7.3.1. Meloxicam
    • 7.3.2. Naproxen
      • 7.3.2.1. Aleve
      • 7.3.2.2. Naprelan
      • 7.3.2.3. Naprosyn
    • 7.3.3. Others
  • 7.4. Biologics
    • 7.4.1. Abatacept
    • 7.4.2. Adalimumab
    • 7.4.3. Etanercept
    • 7.4.4. Infliximab
    • 7.4.5. Rituximab
    • 7.4.6. Tocilizumab
    • 7.4.7. Others
  • 7.5. Corticosteroids
  • 7.6. Others

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Distribution Channel Segment
    • 8.1.2. Market attractiveness index, By Distribution Channel Segment
  • 8.2. Hospital Pharmacies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Retail Pharmacies
  • 8.4. Online Pharmacies
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key region-specific dynamics
    • 9.2.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Type
    • 9.2.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
    • 9.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Type
    • 9.3.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
    • 9.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Rest of South America
  • 9.4. Europe
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Type
    • 9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
    • 9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.4.5.1. Germany
      • 9.4.5.2. U.K.
      • 9.4.5.3. France
      • 9.4.5.4. Spain
      • 9.4.5.5. Italy
      • 9.4.5.6. Rest of Europe
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Type
    • 9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel
    • 9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug Type
    • 9.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

  • 10.1. Competitive scenario
  • 10.2. Competitor strategy analysis
  • 10.3. Market positioning/share analysis
  • 10.4. Mergers and acquisitions analysis

11. Company Profiles

  • 11.1. Pfizer Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Biocon Ltd.
  • 11.3. Coherus BioSciences Inc.
  • 11.4. Livzon Pharmaceutical Group Inc.
  • 11.5. Momenta Pharmaceuticals Inc.
  • 11.6. Mycenax Biotech Inc.
  • 11.7. Oncobiologics Inc.
  • 11.8. Oncodesign SA
  • 11.9. Panacea Biotec Ltd.
  • 11.10. Regeneron Pharmaceuticals Inc.
  • 11.11. Sandoz International GmbH
  • 11.12. UCB SA List not Exhaustive*

12. DataM

  • 12.1. Appendix
  • 12.2. About us and services
  • 12.3. Contact us